Skip to content

Efficacy and safety of acupuncture therapy of Runmu Anshen for Mixed Dry Eye Syndrome:A Multicenter Randomized Clinical Trial

Efficacy and safety of acupuncture therapy of Runmu Anshen for Mixed Dry Eye Syndrome:A Multicenter Randomized Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000673
Enrollment
Unknown
Registered
2024-11-07
Start date
2024-11-20
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mixed Dry Eye Syndrome

Interventions

Artificial tears group:0.1% sodium hyaluronate eye drops: 1~2 drops at a time 4~6 times a day for 8 weeks.
acupuncture therapy of Runmu Anshen group:Body acupuncture choose(EX-HN5 BL1 GB1 BL2 GB20 KI3 SP6 GB37 ST36 LI4 and LR3)Acupuncture was treated 3 times a week for 30 min each time for 8 weeks. Auric

Sponsors

The Third Affiliated Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: According to the diagnostic criteria of dry eye in 2020 Chinese expert consensus on dry eye mixed dry eye is defined as the presence of two or more abnormalities in the schirmer test or tear meniscus height Palpebral margin and palpebral ester assessment eye blink index or combined with autoimmune dry eye. 1. Meeting the diagnostic criteria for dry eye; 2. Aged 18 years to 75 years gender not limited; 3. Have not received any systemic medication within the past 2 weeks; 4. Patients who cooperate well with eye examination and are willing to cooperate with clinical observation trials and are informed consent for the trial protocol.

Exclusion criteria

Exclusion criteria: 1. Patients with hemorrhagic diseases; 2. Patients unable to complete the follow-up as scheduled; 3. Patients who have been taking sedative antidepressant and anti-anxiety drugs for a long time; 4. Patients without other ocular or systemic disease histories and who are not pregnant or lactating.

Design outcomes

Primary

MeasureTime frame
Ocular surface disease index scale;cornea fluorescein staining;BUT;Conjunctival Impression Cytology;

Secondary

MeasureTime frame
Tear meniscus height;meibum quality score;Self-rating depression Scale;Meiboscore; meibomian gland expressibility scoreity score;Pittsburgh Sleep Quality Index;Self-rating anxiety scale;lid margin abnormalities;

Countries

China

Contacts

Public ContactLiu Jing

The Third Affiliated Hospital of Zhejiang Chinese Medical University

liujing0113@126.com+86 152 6856 8009

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 14, 2026